Gilead and Ar­cel­lx spot­light safe­ty of mul­ti­ple myelo­ma cell ther­a­py, dose first pa­tient in Phase 3

Gilead and Ar­cel­lx’s ear­ly tri­al da­ta on their mul­ti­ple myelo­ma cell ther­a­py show that pa­tients saw no cas­es of cer­tain de­layed neu­ro­tox­i­c­i­ties, which are as­so­ci­at­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA